Selected publications
-
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
The Lancet Haematology.
2020
Academic Article
GET IT
Times cited: 1 - Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020 Academic Article GET IT
-
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.
Leukemia.
2020
Academic Article
GET IT
Times cited: 1 -
Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy.
Leukemia and Lymphoma.
2020
Article
GET IT
Times cited: 1 - Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia. 2020 Academic Article GET IT
- The therapeutic landscape for cells engineered with chimeric antigen receptors. Nature Biotechnology. 2020 Academic Article GET IT
-
Paradigms for Precision Medicine in Epichaperome Cancer Therapy.
Cancer Cell.
2019
Academic Article
GET IT
Times cited: 3 -
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia.
Clinical Epigenetics.
2019
Academic Article
GET IT
Times cited: 2 -
Rational targeting of cooperating layers of the epigenome yields enhanced therapeutic efficacy against AML.
Cancer Discovery.
2019
Academic Article
GET IT
Times cited: 4 - Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma. Neoplasia (United States). 2019 Academic Article GET IT
-
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
The Lancet Haematology.
2019
Academic Article
GET IT
Times cited: 11 -
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Journal of Clinical Oncology.
2019
Academic Article
GET IT
Times cited: 79 -
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Blood.
2019
Academic Article
GET IT
Times cited: 38 -
Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes.
Biology of Blood and Marrow Transplantation.
2019
Academic Article
GET IT
Times cited: 1 -
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.
Leukemia.
2019
Academic Article
GET IT
Times cited: 5 - Chronic Myelogenous Leukemia Diagnosed in the Setting of Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. International Journal of Surgical Pathology. 2019 Academic Article GET IT
-
Clonal Hematopoiesis and risk of Acute Myeloid Leukemia.
Best Practice and Research: Clinical Haematology.
2019
Report
GET IT
Times cited: 2 -
Clonal Hematopoiesis and therapy related MDS/AML.
Best Practice and Research: Clinical Haematology.
2019
Report
GET IT
Times cited: 5 -
FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels.
Nature Nanotechnology.
2019
Academic Article
GET IT
Times cited: 11 -
Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia.
Haematologica.
2018
Academic Article
GET IT
Times cited: 5 -
Somatic mutations precede acute myeloid leukemia years before diagnosis.
Nature Medicine.
2018
Academic Article
GET IT
Times cited: 84 -
Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML.
New England Journal of Medicine.
2018
Academic Article
GET IT
Times cited: 216 - Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma. 2018 Academic Article GET IT
- Enasidenib for relapsed/refractory acute myeloid leukemia with IDH2 mutations: Optimizing the patient experience. Clinical Advances in Hematology and Oncology. 2018 Academic Article GET IT
-
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Blood.
2018
Review
GET IT
Times cited: 158 -
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
Cancer.
2018
Academic Article
GET IT
Times cited: 24 -
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.
Biology of Blood and Marrow Transplantation.
2018
Academic Article
GET IT
Times cited: 2 -
Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
Clinical Lymphoma, Myeloma and Leukemia.
2018
Academic Article
GET IT
Times cited: 4 -
Low Clinical Trial Accrual of Patients With Myelodysplastic Syndromes: Causes and Potential Solutions.
Cancer.
2018
Academic Article
GET IT
Times cited: 1 -
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.
Leukemia.
2018
Academic Article
GET IT
Times cited: 50 -
Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R.
American Journal of Hematology.
2018
Academic Article
GET IT
Times cited: 2 -
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. Best supportive care.
Blood Cancer Journal.
2017
Information Resource
GET IT
Times cited: 6 -
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
Blood.
2017
Academic Article
GET IT
Times cited: 40 -
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Blood.
2017
Academic Article
GET IT
Times cited: 369 -
Practical implications of the 2016 revision of the world health organization classification of lymphoid and myeloid neoplasms and acute leukemia.
Journal of Clinical Oncology.
2017
Review
GET IT
Times cited: 24 -
Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia.
Leukemia and Lymphoma.
2017
Academic Article
GET IT
Times cited: 3 -
CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.
Leukemia and Lymphoma.
2017
Academic Article
GET IT
Times cited: 2 -
The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.
Cancer.
2017
Academic Article
GET IT
Times cited: 15 -
Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.
Journal of Molecular Diagnostics.
2017
Academic Article
GET IT
Times cited: 27 -
Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium.
Leukemia.
2017
Academic Article
GET IT
Times cited: 20 -
Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents.
Journal of Clinical Oncology.
2017
Academic Article
GET IT
Times cited: 30 -
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: Phase 2 results from a multicentre, randomised, phase 1/2 trial.
The Lancet Oncology.
2017
Academic Article
GET IT
Times cited: 58 -
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes.
Cancer.
2017
Academic Article
GET IT
Times cited: 45 -
Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)*.
Leukemia and Lymphoma.
2016
Academic Article
GET IT
Times cited: 7 -
The application of mass spectrometry to leukemia drug discovery.
Expert Opinion on Drug Discovery.
2016
Academic Article
GET IT
Times cited: 1 -
A multi-institution phase i trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML).
Clinical Cancer Research.
2016
Academic Article
GET IT
Times cited: 46 - Are we ready for precision medicine in acute myeloid leukemia?. Clinical Advances in Hematology and Oncology. 2016 Article GET IT
- Are we ready for precision medicine in acute myeloid leukemia?. Clinical Advances in Hematology and Oncology. 2016 Comment
-
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia.
Nature Medicine.
2016
Academic Article
GET IT
Times cited: 121 -
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure.
Haematologica.
2016
Information Resource
GET IT
Times cited: 20 -
Clofarabine as a bridge to hematopoietic stem cell transplant.
Leukemia and Lymphoma.
2016
Academic Article
GET IT
Times cited: 1 -
Allogeneic Transplantation for Patients with Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
Clinical Lymphoma, Myeloma and Leukemia.
2016
Academic Article
GET IT
Times cited: 6 -
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.
Leukemia.
2016
Academic Article
GET IT
Times cited: 29 -
MSI2 is required for maintaining activated myelodysplastic syndrome stem cells.
Nature Communications.
2016
Academic Article
GET IT
Times cited: 14 -
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.
Future Oncology.
2016
Academic Article
GET IT
Times cited: 15 -
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.
Leukemia Research.
2016
Academic Article
GET IT
Times cited: 11 -
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): A randomised, controlled, phase 3 trial.
The Lancet Oncology.
2016
Academic Article
GET IT
Times cited: 61 -
The epichaperome is an integrated chaperome network that facilitates tumour survival.
Nature.
2016
Academic Article
GET IT
Times cited: 77 -
In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche.
Leukemia.
2015
Academic Article
GET IT
Times cited: 20 -
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species.
Cell Reports.
2015
Academic Article
GET IT
Times cited: 9 -
Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?.
American Journal of Hematology.
2015
Academic Article
GET IT
Times cited: 19 - Evolving treatments in acute myeloid leukemia. Clinical Advances in Hematology and Oncology. 2015 Academic Article GET IT
-
Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.
Leukemia and Lymphoma.
2015
Academic Article
GET IT
Times cited: 15 -
Phase i trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome.
Leukemia and Lymphoma.
2015
Academic Article
GET IT
Times cited: 3 -
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: A multicentre, randomised, dose-escalation phase 1 study.
The Lancet Oncology.
2015
Academic Article
GET IT
Times cited: 152 -
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
Cytometry Part A.
2015
Academic Article
GET IT
Times cited: 47 -
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): A randomised, controlled, double-blind, multinational, phase 3 study.
The Lancet Oncology.
2015
Academic Article
GET IT
Times cited: 85 -
Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide.
Journal of Clinical Oncology.
2014
Academic Article
GET IT
Times cited: 34 -
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.
Journal of Clinical Oncology.
2014
Academic Article
GET IT
Times cited: 77 -
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
Science Translational Medicine.
2014
Academic Article
GET IT
Times cited: 1132 -
Epigenetic targeting and personalized approaches for AML.
Hematology.
2014
Review
GET IT
Times cited: 10 -
Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.
British Journal of Haematology.
2014
Academic Article
GET IT
Times cited: 20 -
Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: A novel potential strategy in acute myelogenous leukemia.
Molecular Cancer Therapeutics.
2014
Academic Article
GET IT
Times cited: 31 - Treating relapsed/refractory all in older patients: Case presentations. Clinical Advances in Hematology and Oncology. 2014 Comment
-
Standardizing the initial evaluation for myelodysplastic syndromes.
Current Hematologic Malignancy Reports.
2013
Review
GET IT
Times cited: 2 -
Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia.
Leukemia and Lymphoma.
2013
Academic Article
GET IT
Times cited: 96 -
A Phase I Study of CPX-351 in Combination with Busulfan and Fludarabine Conditioning and Allogeneic Stem Cell Transplantation in Adult Patients with Refractory Acute Leukemia.
Biology of Blood and Marrow Transplantation.
2013
Academic Article
GET IT
Times cited: 9 -
Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies.
Leukemia and Lymphoma.
2013
Academic Article
GET IT
Times cited: 68 -
A randomized controlled trial of romiplostim in patients with low-or intermediate-risk myelodysplastic syndrome receiving decitabine.
Leukemia and Lymphoma.
2013
Academic Article
GET IT
Times cited: 50 -
Pregnancy in a woman with chronic neutrophilic leukemia.
Obstetrics and Gynecology.
2013
Academic Article
GET IT
Times cited: 1 -
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.
Leukemia Research.
2012
Review
GET IT
Times cited: 22 -
Current treatment of acute myeloid leukemia.
Current Opinion in Oncology.
2012
Review
GET IT
Times cited: 91 -
RBC-transfusion guidelines update.
Leukemia Research.
2012
Information Resource
GET IT
Times cited: 6 -
Are low-intensity induction strategies better for older patients with acute myeloid leukemia?.
Leukemia Research.
2012
Academic Article
GET IT
Times cited: 8 -
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.
Blood.
2012
Academic Article
GET IT
Times cited: 20 -
Novel approaches to the treatment of acute myeloid leukemia.
Hematology.
2011
Review
GET IT
Times cited: 61 -
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.
Blood.
2011
Academic Article
GET IT
Times cited: 92 -
Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome.
Leukemia Research.
2011
Academic Article
GET IT
Times cited: 8 -
First-in-man study of CPX-351: A liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
Journal of Clinical Oncology.
2011
Academic Article
GET IT
Times cited: 178 -
What are RBC-transfusion-dependence and -independence?.
Leukemia Research.
2011
Information Resource
GET IT
Times cited: 48 -
Levels of care: Defining best supportive care in elderly patients with acute myeloid leukemia.
Current Hematologic Malignancy Reports.
2010
Review
GET IT
Times cited: 6 -
Acute myeloid leukemia stem cells: Seek and destroy.
Expert Review of Hematology.
2009
Review
GET IT
Times cited: 32 -
Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: A phase 1 trial.
Leukemia and Lymphoma.
2009
Academic Article
GET IT
Times cited: 40 -
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.
Blood.
2009
Academic Article
GET IT
Times cited: 127 -
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: A preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
Blood.
2009
Academic Article
GET IT
Times cited: 48 -
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
Journal of Clinical Oncology.
2009
Academic Article
GET IT
Times cited: 168 -
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: The START a trial.
Journal of Clinical Oncology.
2009
Academic Article
GET IT
Times cited: 150 - Chemotherapy Foundation Symposium XXVI: Innovative cancer therapy for tomorrow - Voreloxin for acute myelogenous leukemia. P and T. 2008 Article GET IT
-
Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
Cancer.
2008
Academic Article
GET IT
Times cited: 41 -
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Leukemia.
2008
Academic Article
GET IT
Times cited: 44 -
Arsenic and Old Lace: Novel Approaches in Elderly Patients With Acute Myeloid Leukemia.
Seminars in Hematology.
2008
Review
GET IT
Times cited: 5 -
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma.
Leukemia Research.
2007
Academic Article
GET IT
Times cited: 19 -
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma.
Leukemia Research.
2007
Academic Article
GET IT
Times cited: 8 -
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.
Leukemia Research.
2007
Academic Article
GET IT
Times cited: 21 -
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
Blood.
2007
Academic Article
GET IT
Times cited: 316 -
Treatment of acute myeloid leukemia in older patients.
Expert Review of Anticancer Therapy.
2007
Review
GET IT
Times cited: 22 -
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
Journal of Clinical Oncology.
2007
Academic Article
GET IT
Times cited: 66 -
Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
Journal of Clinical Oncology.
2007
Academic Article
GET IT
Times cited: 20 -
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.
Leukemia Research.
2006
Information Resource
GET IT
Times cited: 24 - Treatment strategies for acute myeloid leukemia and myelodysplastic syndromes in the elderly population. P and T. 2006 Conference Paper
-
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
Clinical Cancer Research.
2006
Academic Article
GET IT
Times cited: 40 -
A Study of a Reduced-Intensity Conditioning Regimen Followed by Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancies Using Campath-1H as Part of a Graft-versus-Host Disease Strategy.
Biology of Blood and Marrow Transplantation.
2006
Academic Article
GET IT
Times cited: 10 -
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Leukemia.
2006
Academic Article
GET IT
Times cited: 72 -
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.
Journal of Clinical Oncology.
2005
Academic Article
GET IT
Times cited: 149 -
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
Leukemia Research.
2003
Academic Article
GET IT
Times cited: 20 -
The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate.
Experimental Hematology.
2003
Academic Article
GET IT
Times cited: 38 -
Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia.
Leukemia and Lymphoma.
2002
Academic Article
GET IT
Times cited: 23 -
Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
Clinical Cancer Research.
2002
Academic Article
GET IT
Times cited: 29 -
Pentostatin based non-myeloablative conditioning regimen in patients with high-risk hematologic malignancy.
Blood.
2000
Academic Article
Times cited: 1 -
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis.
Blood.
2000
Academic Article
GET IT
Times cited: 251 -
Interleukin-5 and the regulation of eosinophil production.
Current opinion in hematology.
1999
Academic Article
GET IT
Times cited: 49 - HIV/AIDS case histories: Diagnostic problems. AIDS Patient Care and STDs. 1999 Academic Article GET IT
-
Hepatitis C and B-cell lymphoma.
AIDS Patient Care and STDs.
1998
Review
GET IT
Times cited: 8 -
Epidermal growth factor and basic fibroblast growth factor have independent actions on mesencephalic dopamine neurons in culture.
Journal of Neurochemistry.
1994
Academic Article
GET IT
Times cited: 39